Startseite News
News

Adding Venetoclax to Cladribine and Cytarabine Backbone Improves Response Rates, Outcomes in Older Patients With AML

17-12-2020 13:17

The combination led to high rates of durable remissions and measurable residual disease negativity in older patients with newly diagnosed acute myeloid leukemia, according to results presented at the 2020 ASH Annual Meeting.

Read more

 

Zurück

Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.